VLST Corporation was founded on the belief that the challenge in developing new therapeutics for the treatment of inflammatory diseases is not a lack of suitable targets but the identification of targets that have true therapeutic potential.

VLST has developed a streamlined and efficient proprietary platform that rapidly yields novel biological therapeutic compositions of matter with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders.

The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies.  Moreover, the process used to identify targets also provides a clear path to developing biologic molecules that can be used for target validation studies. The VLST approach reduces the time to clinical development and improves the likelihood of clinical success.